Urolithin A Supplementation for Glucose Metabolism in Healthy Adults
This study is investigating if Urolithin A, a dietary supplement, can improve how your body handles blood sugar (glucose) and insulin. As we age, the body's ability to produce insulin can decrease, leading to higher blood sugar. Researchers believe Urolithin A might help the cells that produce insulin work better. This study will measure insulin levels after taking Urolithin A for 8 weeks. You may be eligible if you are a healthy adult aged 55 to 100 years old. The current recruitment status is unclear.
- Study design
- This is a randomized, triple-masked controlled clinical trial, meaning neither you, your doctor, nor the research team will know if you are receiving Urolithin A or a placebo. The study plans to enroll 180 participants.
- What's involved
- You would have 6 clinic visits over 8 weeks. This includes a physical exam, blood and urine tests, a heart function test, and taking Urolithin A gelcaps by mouth every morning at home.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your insulin secretion will be measured at 4 and 8 weeks after supplementation.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06274749
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Recruiting
NAAges 55+InterventionalBasic scienceNational Institute on Aging (NIA)Government-funded
~180 participants
Updated 2026-09-01 on ClinicalTrials.gov
What's tested:Urolithin APlacebo
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation.
Measured over 8 weeks
Conditions
Where it's being run
1 sites across 1 statesMaryland1
Study leadership
- Josephine M Egan, M.D. · PRINCIPAL_INVESTIGATOR · National Institute on Aging (NIA)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availably for the duration of the study.
Male or female, age \>= 55 years.
Able to speak and read English. (We do not have ready access to interpreters of different languages at the NIA Clinical Unit).
BMI \>= 27.
Ability to take oral medication and be willing to adhere to the daily regimen.
Ability to perform walking and treadmill tests without physical limitations.
In good general health, as evidenced by medical history/physical exam/laboratory results.
Exclusion
History of diabetes requiring treatment with any glucose lowering drug(s).
Fasting glucose \>= 126 on screening visit.
Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment.
Hospitalization within 12 months for myocardial infarction, coronary revascularization or bypass surgery or stroke.
History of autoimmune disease, e.g., Hashimoto s thyroiditis, Myasthenia Gravis or Rheumatoid Arthritis.
Uncontrolled thyroid disease.
Chronic liver disease indicated by medical history or one of the liver enzymes greater than 2 times the normal range.
History of chronic kidney disease or GFR \<60 mL/min/1.73 m\^2.
Anemia (defined as hemoglobin level \<12 g/dl for men or \< 11 g/dl for women).
Poor venous access.
Uncontrolled hypertension as judged by the Investigator.
History of significant GI disease, e.g., IBS, Crohn s disease.
Active cancer or has had treatment for cancer in the last 1 year.
Medical condition requiring absolute and continuous need for long-term treatment with antibiotics, corticosteroids, immunosuppressors.
Currently pregnant or a nursing mother due to possible changes in hormones and metabolism.
History of, or laboratory evidence of HIV virus infection at Screening Visit.
History of, or laboratory evidence of Hepatitis B or C at Screening Visit.
Positive urine drug screen at Screening Visit (unless taking prescribed medication and at the discretion of the PI).
Reports claustrophobia and/or is not eligible to have an MRI as per the MRI eligibility form.
Weight \>= 300 lbs (MRI scanner weight limit).
Hip or knee replacement or other medical condition that prevents MRI research scans from being performed.
Diagnosed with cognitive impairment that clearly prevents the participant from providing informed consent.
Current smoker or tobacco use in the past year.
History of substance abuse, including marijuana use in the past year.
On average, consumes more than 1 alcoholic drink per day.
Any other condition which in the investigator s opinion may adversely affect the subject s ability to complete the study or its measures or which may pose significant risk to the subject.
What this trial measures
- To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation.8 weeks
Study visits 1 - 5